Weight Loss Drugs Won’t Eat Into Food Industry Profits, Nestlé CEO Says

  • 📰 Forbes
  • ⏱ Reading Time:
  • 12 sec. here
  • 11 min. at publisher
  • 📊 Quality Score:
  • News: 39%
  • Publisher: 53%

Mark Schneider ニュース

Nestle,Glp-1,Ozempic

Robert Hart is a senior reporter for Forbes covering science, technology and health with a frequent focus on artificial intelligence, space, weight loss drugs and emerging technologies. He joined Forbes in 2020 and is based in London. Rob has covered everything from the billionaire space race, the health impacts of overturning Roe v.

What If Trump Jurors Can’t Reach A Verdict? Here’s What The Hush Money Case Judge Can Do To End A Hung Jury.Nestlé is tapping into the lucrative weight loss drug market by catering to customers’ “shifting” nutritional needs, CEO Mark SchneiderCNBC on Thursday, an optimistic pivot from one of the industry’s biggest players in the face of dire early predictions suggesting wildly popular drugs like Ozempic, Mounjaro and Wegovy would take a bite out of the food industry.

Schneider said the different needs of people using weight loss drugs open up a big market opportunity for companies like Nestlé, which he said has big plans to respond to what has rapidly become a “major consumer trend.”

このニュースをすぐに読めるように要約しました。ニュースに興味がある場合は、ここで全文を読むことができます。 続きを読む:

 /  🏆 394. in JP
 

コメントありがとうございます。コメントは審査後に公開されます。

日本 最新ニュース, 日本 見出し

Similar News:他のニュース ソースから収集した、これに似たニュース記事を読むこともできます。

Weight Loss Drugs Won’t Eat Into Food Industry Profits, Nestlé CEO SaysRobert Hart is a senior reporter for Forbes covering science, technology and health with a frequent focus on artificial intelligence, space, weight loss drugs and emerging technologies. He joined Forbes in 2020 and is based in London. Rob has covered everything from the billionaire space race, the health impacts of overturning Roe v.
ソース: ForbesTech - 🏆 318. / 59 続きを読む »